Menu

The Trouble With Sex in Science

Researchers argue for the consideration of hormones and sex chromosomes in preclinical experiments.

Aug 9, 2016
Kerry Grens

PIXABAY, CLIKER-FREE-VECTOR-IMAGESMale animals and male-derived tissues and cells are largely overrepresented in basic science. But in studying mostly male specimens, researchers miss out on an opportunity to understand how hormones and sex chromosomes may impact disease risks and outcomes, according to Deborah Clegg of the Cedars-Sinai Diabetes and Obesity Research Institute and coauthors.

“Researchers are encouraged to critically think of the impact that their experimental design has on the hormonal profile and to accurately analyze the data focusing on the impact of sex, not only of the individual being studied but also of the cell in a dish,” the researchers wrote in Cell Metabolism today (August 9).

Clegg said in a press release that sex considerations go beyond male or female—to, say, whether a woman is postmenopausal or taking birth control pills. “Without addressing all of these variables in your analysis, you’re still not accurately reflecting the impact of hormones and chromosomes in your research.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.